Phase 1 study of entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in children, adolescents, and young adults with recurrent or refractory solid tumors Meeting Abstract
| Authors: | Desai, A. V.; Brodeur, G. M.; Foster, J.; Berg, S. L.; Basu, E. M.; Shusterman, S.; Sabnis, A. J.; Macy, M.; Yoon, J.; Gauvain, K.; Esquibel, V.; Maneval, E. C.; Multani, P. S.; Fox, E. |
| Abstract Title: | Phase 1 study of entrectinib (RXDX-101), a TRK, ROS1, and ALK inhibitor, in children, adolescents, and young adults with recurrent or refractory solid tumors |
| Meeting Title: | 54th Annual Meeting of the American Society of Clinical Oncology (ASCO) |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 36 |
| Issue: | 15 Suppl. |
| Meeting Dates: | 2018 Jun 1-5 |
| Meeting Location: | Chicago, IL |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2018-05-20 |
| Start Page: | 559s |
| Language: | English |
| ACCESSION: | WOS:000442916003525 |
| DOI: | 10.1200/JCO.2018.36.15_suppl.10536 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 10536 -- Source: Wos |
